×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
EDIT – editas medicine, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
EDIT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/15
10:33 am
edit
Editas Medicine (NASDAQ:EDIT) was upgraded by analysts at Chardan Capital from a "hold" rating to a "strong-buy" rating.
Low
Report
Editas Medicine (NASDAQ:EDIT) was upgraded by analysts at Chardan Capital from a "hold" rating to a "strong-buy" rating.
11/10
07:11 am
edit
Editas Medicine Announces Third Quarter 2025 Results and Business Updates [Yahoo! Finance]
Medium
Report
Editas Medicine Announces Third Quarter 2025 Results and Business Updates [Yahoo! Finance]
11/10
07:00 am
edit
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
Medium
Report
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
11/3
09:00 am
edit
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
Low
Report
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
10/24
12:21 pm
edit
Editas Medicine (NASDAQ:EDIT) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Editas Medicine (NASDAQ:EDIT) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
10/9
11:01 am
edit
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
Low
Report
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
10/8
12:20 pm
edit
Editas Medicine (NASDAQ:EDIT) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Editas Medicine (NASDAQ:EDIT) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
10/6
09:00 am
edit
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
Medium
Report
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/4
04:39 pm
edit
Form 4 Editas Medicine, Inc. For: Dec 03 Filed by: Burkly Linda
Low
Report
Form 4 Editas Medicine, Inc. For: Dec 03 Filed by: Burkly Linda
12/4
04:38 pm
edit
Form 4 Editas Medicine, Inc. For: Dec 03 Filed by: Parison Amy
Low
Report
Form 4 Editas Medicine, Inc. For: Dec 03 Filed by: Parison Amy
12/4
04:38 pm
edit
Form 4 Editas Medicine, Inc. For: Dec 03 Filed by: O'Neill Gilmore Neil
Low
Report
Form 4 Editas Medicine, Inc. For: Dec 03 Filed by: O'Neill Gilmore Neil
12/1
05:07 pm
edit
Form 144 Editas Medicine, Inc. Filed by: O'Neill Gilmore Neil
Medium
Report
Form 144 Editas Medicine, Inc. Filed by: O'Neill Gilmore Neil
11/10
04:06 pm
edit
Form 10-Q Editas Medicine, Inc. For: Sep 30
Medium
Report
Form 10-Q Editas Medicine, Inc. For: Sep 30
11/10
07:06 am
edit
Form 8-K Editas Medicine, Inc. For: Nov 10
Medium
Report
Form 8-K Editas Medicine, Inc. For: Nov 10
10/9
04:31 pm
edit
Form 8-K Editas Medicine, Inc. For: Oct 09
Medium
Report
Form 8-K Editas Medicine, Inc. For: Oct 09
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/7
Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating.
7.2%
11/12 Q3/2019 9/30/2019 EPS -0.660 ZacksConsensus -0.730 ActVsEst 0.070 - Beat 6.9%
3/5 Editas Medicine Inc (NASDAQ: EDIT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $55.00 price target on the stock. 5.2%
3/4 Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10 5.1%
8/29 Editas Medicine to Participate in Upcoming Investor Conferences 4.5%
6/14 Form 4 Editas Medicine, Inc. For: Jun 12 Filed by: Hirsch Andrew 4.0%
10/19 Companies Like Editas Medicine (NASDAQ:EDIT) Are In A Position To Invest In Growth [Yahoo! Finance News] 3.7%
11/13 Editas Expands Its Celgene Partnership After Another Strong Quarter [The Motley Fool] 3.7%
11/28 Editas Medicine Inc (NASDAQ: EDIT) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 3.6%
5/4 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.4%
11/12 Q3/2019 9/30/2019 EPS -0.660 ZacksConsensus -0.730 ActVsEst 0.070 - Beat 6.9%
3/5 Editas Medicine Inc (NASDAQ: EDIT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $55.00 price target on the stock. 5.2%
3/4 Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10 5.1%
8/29 Editas Medicine to Participate in Upcoming Investor Conferences 4.5%
6/14 Form 4 Editas Medicine, Inc. For: Jun 12 Filed by: Hirsch Andrew 4.0%
10/19 Companies Like Editas Medicine (NASDAQ:EDIT) Are In A Position To Invest In Growth [Yahoo! Finance News] 3.7%
11/13 Editas Expands Its Celgene Partnership After Another Strong Quarter [The Motley Fool] 3.7%
11/28 Editas Medicine Inc (NASDAQ: EDIT) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 3.6%
5/4 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.4%
TOP News Decliners
5/10
Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.
-10.9%
4/1 Better Buy: Editas Medicine vs Sangamo Therapeutics [The Motley Fool] -8.1%
2/26 Form S-8 Editas Medicine, Inc. -6.8%
2/21 Editas Medicine Inc (NASDAQ: EDIT) is now covered by analysts at Wells Fargo & Co. They set an "equal weight" rating and a $28.00 price target on the stock. -6.7%
2/22 Better Buy: Editas Medicine vs. Intellia [The Motley Fool] -6.2%
7/30 Editas Medicine to Host Conference Call Discussing Second Quarter 2019 Results and Corporate Update -5.8%
8/27 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.1%
4/30 Editas Medicine to Host Conference Call Discussing First Quarter 2020 Results and Corporate Update -4.9%
11/26 Better Buy: Editas Medicine or Sangamo Therapeutics? [The Motley Fool] -4.6%
3/20 Editas Medicine Inc (NASDAQ: EDIT) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.6%
4/1 Better Buy: Editas Medicine vs Sangamo Therapeutics [The Motley Fool] -8.1%
2/26 Form S-8 Editas Medicine, Inc. -6.8%
2/21 Editas Medicine Inc (NASDAQ: EDIT) is now covered by analysts at Wells Fargo & Co. They set an "equal weight" rating and a $28.00 price target on the stock. -6.7%
2/22 Better Buy: Editas Medicine vs. Intellia [The Motley Fool] -6.2%
7/30 Editas Medicine to Host Conference Call Discussing Second Quarter 2019 Results and Corporate Update -5.8%
8/27 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.1%
4/30 Editas Medicine to Host Conference Call Discussing First Quarter 2020 Results and Corporate Update -4.9%
11/26 Better Buy: Editas Medicine or Sangamo Therapeutics? [The Motley Fool] -4.6%
3/20 Editas Medicine Inc (NASDAQ: EDIT) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: